PARP1-dependent DNA-protein crosslink repair
DNA-protein crosslinks (DPCs) are toxic lesions that inhibit DNA related processes. Post-translational modifications (PTMs), including SUMOylation and ubiquitylation, play a central role in DPC resolution, but whether other PTMs are also involved remains elusive. Here, we identify a DPC repair pathway orchestrated by poly-ADP-ribosylation (PARylation). Using Xenopus egg extracts, we show that DPCs on single-stranded DNA gaps can be targeted for degradation via a replication-independent mechanism. During this process, DPCs are initially PARylated by PARP1 and subsequently ubiquitylated and degraded by the proteasome. Notably, PARP1-mediated DPC resolution is required for resolving topoisomerase 1-DNA cleavage complexes (TOP1ccs) induced by camptothecin. Using the Flp-nick system, we further reveal that in the absence of PARP1 activity, the TOP1cc-like lesion persists and induces replisome disassembly when encountered by a DNA replication fork. In summary, our work uncovers a PARP1-mediated DPC repair pathway that may underlie the synergistic toxicity between TOP1 poisons and PARP inhibitors.
Authors
- Marta Oliva-Santiago (ORCID: https://orcid.org/0000-0002-2935-8810)
- Jesper Q. Svejstrup (ORCID: https://orcid.org/0000-0003-4964-6147)
- Michael L. Nielsen (ORCID: https://orcid.org/0000-0002-0067-9039)
- Julien P. Duxin (ORCID: https://orcid.org/0000-0001-9389-4186)
- Ulrike Kühbacher (ORCID: https://orcid.org/0000-0001-6472-8883)
- Ivo A. Hendriks (ORCID: https://orcid.org/0000-0002-1439-3701)
- A. Barbara Dirac-Svejstrup (ORCID: https://orcid.org/0000-0003-0341-6944)
- Keith W. Caldecott
- Zita Fábián (ORCID: https://orcid.org/0000-0002-2259-1054)
- Nicolai Balle Larsen (ORCID: https://orcid.org/0000-0001-5105-7056)
- Ellen S. Kakulidis
- Junhui Wang (ORCID: https://orcid.org/0000-0002-6333-0096)
- Xueyuan Leng (ORCID: https://orcid.org/0000-0003-3063-2757)
Institutions
- University of Copenhagen (DK)
- University of Sussex (GB)
- Novo Nordisk Foundation (DK)
Publication Details
- Journal
- Nature Communications
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1038/s41467-024-50912-x
- Citations
- 21
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 5.93
Funders
- European Commission
- Novo Nordisk
- Novo Nordisk Fonden
- Medical Research Council